Hyperuricaemia is a serious purine metabolism disorder which may lead to gout, nephrolithiasis and other serious health problems. As a key enzyme responsible for the hydrolysis of uric acid to allantoin in the purine degradation pathway, uricase, especially recombinant uricase, shows great potential in the therapy of hyperuricaemia. In this paper, baboon uricase gene attached with Trx and hexahistidine tags was cloned and expressed in Escherichia coli Rosetta (DE3). The target protein formed a soluble structure in the cytoplasm at 25 °C, with a gradual enrichment in the induction time course, reaching its highest level at 6 h. After purification and maturation, the final yield of mature baboon uricase was 136.0 mg/L with enzyme activity of 17.93 U/ mg. The K m of recombinant uricase was 6.15 μmol/L. And the optimum temperature and pH of the prepared uricase were 37 °C and 8.2, respectively. MALDI-TOF-MS/MS characterization confirmed the prepared protein was identical with the native baboon uricase. These results showed that the baboon uricase gene had been expressed effectively in E. coli and the obtained protein possessed promising enzymatic properties, which gives a new candidate for the therapy of hyperuricaemia.
Introduction
Uricase or urate oxidase (UOX, EC 1.7.3.3), the last enzyme in the metabolic pathway of purine nucleotides, determines the final breakdown product of purine nucleotides. Human beings and most primates, due to a non-sense mutation that occurred at some point in evolution in the uricase gene in their genome (5, 6, 12) , cannot produce uricase, which subsequently brings about a higher physiological concentration of urate, close to its limit of solubility in people (6) . Urate scavenges harmful radicals in our body. however, in conjuction with genetic or environmental (especially dietary) factors, urate may cause gout, nephrolitiasis, and vascular diseases (8) . compared to chemical drugs used for decrease of uric acid, uricase is considered to be a promising candidate for the treatment of gout or hyperuricaemia for its catalytic efficiency on uric acid. To date, several microorganism-and plant-derived uricases have been successfully obtained via recombinant technology (1, 2, 3, 4, 10, 11) and applied in therapeutic use for control of gout and hyperuricaemia-related diseases (7, 9) . however, because of the evolutionary gap between the producers and human beings, the biosafety and biocompatibility of these uricases was a problem when used in human patients. From this point of view, among the animals possessing an active uricase gene, the baboon has a closest evolutionary relationship with human beings, so baboon uricase might have better biocompatibility than other native uricases. However, to the best of our knowledge, baboon uricase (bUOX) has not been produced till now. Therefore, we tried to clone and express the gene encoding baboon uricase (rbUoX). the induction conditions were optimized to avoid the aggregation of target protein in the cytoplasm. The amino acid composition and kinetic parameters were determined to characterize the prepared protein.
Materials and Methods

Construction of pET-rbUOX plasmid
The target gene was amplified via splicing by overlap extension PCR (SOE) and then inserted into the corresponding sites of pet32a(+) expression vector (novagen) ( Fig. 1) 
Expression of rbUOX in Rossetta (DE3)
The transformant was first grown in 100 mL LB with 100 μmol/L Ampicillin at 37 °C until the culture reached an A 600 of 0.8-1.0 (approximately 3 h). Then, isopropylthio-β-D-galactoside (IPTG) was added into the culture to a final concentration of 1 mmol/L. Meanwhile, the temperature was reduced to 25 °C, 30 °C, and 37 °C, respectively. After induction for 8 h, samples were taken and analyzed by 10 % SDS-PAGE to ensure the influence of temperature on the expression of target protein.
Moreover, the culture was induced at 25 °C for different hours (2 h, 4 h, 6 h, and 8 h, respectively) to determine the optimized induction time. To ensure the form of the expressed protein in the cytoplasm, the liquid culture was centrifuged at 10000×g for 2 min and then the supernatant was removed. The cell pellets were resuspended in 1× Ni 2+ -NTA Bind Buffer (containing 300 mmol/L NaCl, 50 mmol/L sodium phosphate buffer, and 10 mmol/L imidazole, pH 8.0) with an equal volume to that of the liquid culture. next, the cell pellets were lysed according to the manufacturer's manual (No. TB273, Novagen); and then the cell lysate, supernatant and precipitate suspension of lysate were loaded on 10 % SDS-PAGE.
Purification of rbUOX fusion
The supernatant of the cell lysate was loaded on Ni 2+ -NTA his Bind Resin column (novagen) and eluted under native conditions according to the procedure commended by the manufacturer (No. TB273). Thereafter, the purified protein was analyzed by 10 % SDS-PAGE. Quantity analysis of the target protein was performed as the method of bicinchoninic acid (BCA).
Characterization of expressed uricase
The One unit (U) was defined as the amount of enzyme necessary to transform 1 μmol of uric acid into allantoin in 1 min. And the enzyme activity of prepared rbUOX was calculated by the following equation:
where U is the enzyme activity of prepared uricase (U/mg); ΔA is the decrease in absorbance at 293 nm per min of reaction; Vt is the volume of reaction mixture (mL); c is the concentration of rbUOX solution (mg/mL); n is the dilution factor of rbUOX The standard curve of BCA utilized in this section is shown in the Online Supplementary Appendix (Fig. S1, www. diagnosisnet.com/bbeq). The mature uricase was determined by means of MALDI-TOF-MS/MS. The target protein band was excised from the SDS-PAGE gel and destained with 15 mmol/L potassium ferricyanide and 50 mmol/L sodium thiosulfate (1:1, v/v) for 30 min at room temperature. After being washed twice with deionized water and shrunk by dehydration in acetonitrile, the sample was swollen in digestion buffer containing 20 mmol/L ammonium bicarbonate and 12.5 ng/μL trypsin (1:1, v/v) at 4 °C for 30 min. Then the gels were digested for more than 12 h at 37 °C. Peptides were extracted twice with 0.1 % trifluoroacetic acid and 50 % acetonitrile (1:1, v/v) and then subjected to a 4700 Proteomics Analyzer (Applied Biosystem 4700).
Results and Discussion
Construction of pET-rbUOX plasmid Fig. 2 indicates that the rbUOX gene was successfully amplified by SOE with a molecular weight of 973 bp (Lanes 1 and 2). After ligation to pCR 2.1 and sequencing, the baboon uricase gene was excised from pCR 2.1 by Bgl ii and EcoR I and then inserted into the corresponding sites of the pet32a(+) vector. Fig. 3A shows the rbUOX gene expressed under different temperatures. Since lower temperatures are beneficial for prevention of inclusion body formation in E.coli, we fixed 25 °C as the final induction temperature. Fig. 3B indicates that 6 h were enough for the expression of the target gene in E. coli Rosetta (DE3) at 25 °C. Fig. 3C revealed the expressed protein located in the cytoplasm with a soluble form (Lane 2). These results indicated that a highly soluble fusion partner (Trx-tag) and lower induction temperature (25 °C) were beneficial for the target protein to form its correct structure in the cytoplasm. Fig. 3D shows the target fusion protein purified by nickel affinity chromatography (Lane 1). BCA detection revealed the production and the final yield of the expressed protein were 170.2 mg/l and 136.0 mg/l, respectively ( Table 1) . the recovery of the target protein was 79.91 %, which indicated the target protein could be separated effectively by nickel affinity chromatography. Fig. 4 showed the Biological activity assay of the matured rbUOX at different temperatures and pH, from which we can find the prepared uicase exhibits maximum activity at 37 °C (Fig. 4A ) and the optimum ph is 8.2 (Fig. 4B) . the enzyme activity of the obtained protein was 17.93 U/mg. The Lineweaver-Burk double-reciprocal plot revealed that the Km of the prepared uricase was 6.15 μmol/L (Fig. S2 in the Online Supplementary Appendix, www.diagnosisnet.com/bbeq).
Expression and purification of the rbUOX in Rossetta (DE3)
Characterization of expressed uricase
As to MALDI-TOF-MS/MS determination of the obtained protein, Mascot search results predicted that the protein matched the native baboon uricase with a top score of 375, which was much greater than 75, the basic value for the probability of protein (p < 0.05) ( Table S2 in the Online Supplementary Appendix, www.diagnosisnet.com/bbeq). Table 3 gives detailed the information about the peptides detected by MS/MS that matched the native baboon uricase. Fig. 6 presents the mass-spectrogram of the matched peptide, KNDELEFVR. These results confirmed the obtained protein had an identical primary structure with that of native baboon uricase and possessed a molecular mass of 34 956 Da. 
Conclusions
In this paper, we developed a simple but effective process for the production of recombinant baboon uricase in E. coli. the uricase gene was successfully expressed in the host cell. The target protein could be purified by affinity chromatography. The production and the final yield of uricase were satisfactory. The results from the characterization of the prepared protein indicated that the uicase possessed identical amino acids with the native baboon uircase and exhibited excellent enzymatic activity in vitro. We hope this study would give a guide for the mass production of uricase and supply a new candidate for the therapy of hyperuricaemia and related diseases.
